Search Results 1061-1070 of 16547 for monoclonal antibody

1. MC230813 A Study of Golcadomide with Rituximab prior to CAR-T with Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL) - Mayo Clinic

   Exception: Monoclonal and bispecific antibodies is acceptable. Prior therapy with golcadomide ≤4 weeks prior to Registration. Prior autologous SCT ≤3 ...

2. A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma - Mayo Clinic

   Known hypersensitivity to another monoclonal antibody that cannot be controlled with standard measures (e.g., antihistamines and corticosteroids). Inability ...

3. Cancer blood tests: Lab tests used in cancer diagnosis - Mayo Clinic

   Monoclonal antibody drugs · Mort Crim and Cancer · Mouth sores caused by cancer treatment: How to cope · MRI · Muscle pain · Needle biopsy · Night sweats · No ...

4. Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies - Mayo Clinic

   For prior biological therapies, eg, monoclonal antibodies with a half-life longer than 3 days, the interval must be at least 28 days prior to the first dose of ...

5. Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease - Mayo Clinic

   Prior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 3 months prior to start of therapy. Uncontrolled infectious complications not ...

6. Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis - Mayo Clinic

   - Receipt of any marketed or investigational biologic products (monoclonal or polyclonal antibody) within one year of the screening visit - Receipt of ...

7. A Study to Evaluate Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma - Mayo Clinic

   Known hypersensitivity to platinum, paclitaxel, another monoclonal antibody, or any of the excipients that cannot be controlled with standard measures (e.g., ...

8. IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy - Mayo Clinic

   ... Antibody by cell based assay. And ≥ 2 seizures per week (mean of total over 1 week); And duration of epilepsy < 3 years; Male or female between the ages of ...

9. Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization - Mayo Clinic

   About this study. The purpose of this trial is to determine the safety and efficacy of eculizumab in the prevention of antibody mediated rejection (AMR) in ...

10. A Study to Evaluate EAA181 to Treat Newly-diagnosed Multiple Myeloma - Mayo Clinic

    ≥ 200 mg/24 hours of monoclonal protein on a 24-hour urine protein electrophoresis. ... Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease).